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schedule. There were no acute toxicities attributable to cellcept
observed in patients on IV therapy. All patients required treatment
with antihypertensive therapy(ies). Grossly infection rates did not
vary from those previously observed in conventionally treated
patients at our center. 18/21 patients engrafted neutrophils be-
tween day 9 and 52. Of the three patients who did not engraft, 2
died of infectious complications, one died of VOD and multi-
system organ failure. Of the 18 patients, evaluable for GvHD
follow-up ranged between 34 and 693 days (median 108 days), 6
patients had 0 grade I, 10 developed grade II, 1 grade III, and 1
grade 4 GVHD. Follow-up is too short to comment on the inci-
dence of chronic GvHD, but to date, 4 of 7 patients followed for
	100 days have developed chronic GvHD. While this data is early,
it appears that the incidence of both acute and chronic GvHD are
increased compared to previously reported series in patients
treated with cellcept instead of mtx (related bone marrow trans-
plantation) or pred (unrelated cord blood transplantation). En-
graftment in UCBT recipients was not compromised with the use
of IV cellcept administered in the peritransplant period. Additional
patients will need to be tested with this regimen and longer fol-
low-up is necessary to fully deﬁne the risks or beneﬁts of this
therapy.
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OUTCOMES ASSOCIATED WITH A STEROID-CONTAINING ACUTE GVHD
PROPHYLAXIS REGIMEN FOR MATCHED UNRELATED DONOR (MUD)
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Hayes-Lattin, B., Leis, J.F., Curtin, P.T., Dunn, A., Epner, E.,
Fleming, W.H., Kovacsovics, T., Mauro, M.J., Moore, M., Simic, A.,
Subbiah, N., Maziarz, R.T. OHSU Cancer Institute, Center for He-
matologic Malignancies, Portland, OR.
Background: Previously reported randomized trials have
yielded differing conclusions about the addition of steroids to
GVHD prophylaxis for patients undergoing sibling allogeneic
transplant. Prophylaxis with cyclosporine plus methotrexate af-
ter MUD transplant has a reported grade 2–4 acute GVHD
incidence of 74%. MUD transplantation was initiated at OHSU
in 1996 using a 3-drug combination of cyclosporine, methotrex-
ate, and steroids in a single-arm prospective protocol to examine
the incidence and severity of GVHD and survival. Methods:
The analysis included all patients undergoing MUD transplant
who received GVHD prophylaxis with cyclosporine 2 mg/kg iv
BID from day 2, methotrexate 15 mg/m2 iv on day 1 and 10
mg/m2 iv on days 3 and 6, and methylprednisolone 0.25
mg/kg iv BID beginning on day 7 and tapering at day 28.
Patients were stratiﬁed by disease risk per CIBMTR classiﬁca-
tion. Patients with relapse and no GVHD were censored for
GVHD outcomes at therapeutic withdrawal of immunosuppres-
sion. Results: 124 patients received the 3-drug regimen, includ-
ing 50 with low-risk, 43 with intermediate-risk, and 31 with
high-risk disease. One hundred sixteen (94%) of the MUD
grafts were matched at 6 out of 6 HLA-antigens. Eight patients
were not evaluable for GVHD due to death prior to engraft-
ment. The maximum grade of acute GVHD is shown in Table
1. Sixty-four (55%) had grade 0–1 acute GVHD. Fifty-two
(45%) developed grade 2–4 acute GVHD at a median onset of
day 29. Twenty-eight (24%) developed grade 3–4 acute
GVHD. Patients with low-risk disease had a median survival of
29 months and a 5-year OS of 42%, whereas those with inter-
mediate/high-risk had a median survival of 10 months and a
5-year OS of 23%. The rate of disease relapse was 15% for both
the low and intermediate/high-risk groups. Preliminary infec-
tion analysis among 64 patients demonstrated an incidence of all
infections greater than 70%. Conclusions: The observed rate
of grade 3–4 acute GVHD using a 3-drug prophylaxis strategy
that includes steroids after MUD transplantation was low and
delayed in onset when compared to previous trials of 2-drug
combinations. The rate of disease relapse was low and the
overall survival was comparable to other published strategies.
Preliminary analysis suggests a high rate of infections. Addi-
tional analyses are planned to explore rates of chronic GVHD,
as well as other potential steroid-related events such as hyper-
glycemia, musculoskeletal complications, alveolar hemorrhage
or thrombotic microangiopathy (Table).
Maximum Acute GVHD Grade
Number Percent
Grade 0 40 34%
Grade 1 24 21%
Grade 2 24 21%
Grade 3 15 13%
Grade 4 13 11%
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FAILURE OF MEMORY T CELLS TO INDUCE GVHD IS A RESULT OF AN
ABORTIVE ALLORESPONSE
Chen, B.J., DeOliveria, D., Cui, X., Chao, N.J. Duke University
Medical Center, Durham, NC.
We and others previously reported that effector memory T cells
(TEM) can not cause graft-versus-host disease (GVHD). In the
current study, we further investigated the potential of this ap-
proach, the role of central memory T cells (TCM) in GVHD, and
the underlying mechanisms. The study was mainly performed in a
major histocompatibility complex mismatched model (unprimed
C57BL/6 [H2b] to BALB/c [H2d]). Naive T cells
(CD62LCD45RBCD44low), memory T cells (all other T cells
except naive T cells), TCM (both CD62LCD45RB and
CD62LCD45RBCD44high), and TEM (CD62L) were obtained
by cell sorting. An in vivo T cell titration experiment demonstrated
memory T cells are at least 3-log less potent in mediating GVHD
as compared with bulk T cells because infusion of as many as 1 
106 total memory T cells failed to induce GVHD while infusion of
as few as 1  103 bulk T cells was able to induce GVHD in this
model. Because failure of TEM to induce GVHD may be related to
their inability to home to secondary lymphoid organs, we next
asked whether TCM, which have the ability to home to second-
ary lymphoid organs, are able to induce GVHD. The results
indicated that neither TCM nor TEM was able to induce GVHD
even when as many as 1  106 cells were given (Table). All TCM
and TEM recipients survived more than 60 days. In contrast, all
naive T cell recipients died of GVHD within 40 days after
transplantation. These data directly demonstrate that similar to
TEM, TCM can not induce GVHD, suggesting that there are
other mechanisms involved in the inability of memory T cells to
induce GVHD. To further understand these mechanisms, we
then studied memory T cells’ responses to alloantigens in vitro.
As expected, memory T cells failed to elicit cytotoxicity and
proliferated poorly against alloantigens in standard 5-day mixed
lymphocyte culture as compared with both bulk and naive T
cells. However, the proliferation response of memory T cells
were much more comparable with those of bulk and naive T
cells when the culture time was shortened. More strikingly, the
frequencies of IL-2 secreting cells measured by 42-hour ELIS-
POT assay were similar between naive and memory T cells.
These data indicate that memory T cells from unprimed animals
are able to respond to alloantigens initially, but fail to develop
into full potential. The “abortive” immune response, which may
be a feature of non-allospeciﬁc memory T cells in response to
alloantigens, explains why memory T cells can not induce
GVHD (Table).
Central Memory T Cells Cannot Cause GVHD
Groups % Original body weight 60-Day survival
day 21 day 56 -
TCD BM alone 96.4% 95.8% 100%
Naive 70.2% N/A (all dead) 0%
Effector memory 94.2% 93.9% 100%
Central memory 95.6% 98.05 100%
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